SCHEMBL25820900

SCHEMBL25820900

Cc1cc(Nc2cccc(NC(=O)Nc3cccc(Nc4ccccc4)c3)c2)ccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.61
SMARCA4 P51532 1/20 0.61
KDR P35968 2/20 0.52
MAPK1 P28482 2/20 0.52
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52
HSD17B10 Q99714 1/20 0.52
CASP3 P42574 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
KMT2A Q03164 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
PKM P14618 1/20 0.51
NPC1 O15118 5/20 0.50
RAB9A P51151 5/20 0.50
DDX3X O00571 1/20 0.50
ACVRL1 P37023 1/20 0.50
TP53 P04637 1/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24010292 0.93 KMT2A (0.61) SMARCA2SMARCA4KDRKMT2ASMN1; SMN2
SCHEMBL9828922 0.90 SMARCA2 (0.69) SMARCA2SMARCA4KDRMAPK1LMNA
SCHEMBL30232524 0.87 KCNK3 (0.55) KMT2ATP53POLBMEN1
SCHEMBL24003834 0.87 KCNK3 (0.55) KMT2ATP53POLBMEN1
SCHEMBL30290919 0.87 BRAF (0.57) MAPTKMT2APOLBMEN1
SCHEMBL24010657 0.87 BRAF (0.57) MAPTKMT2APOLBMEN1
SCHEMBL7659797 0.84 NPSR1 (0.53) SMARCA2SMARCA4KDRMAPK1LMNA
SCHEMBL31494286 0.84 NPSR1 (0.53) SMARCA2SMARCA4KDRMAPK1LMNA
SCHEMBL25821628 0.83 PORCN (0.55) SMARCA2SMARCA4MAPK1LMNAMAPT
SCHEMBL24003823 0.83 BRAF (0.54) KMT2ASMN1; SMN2NPC1RAB9ANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219927-A1 AKT3 MODULATORS AKT3, AKT2, PIK3CA SMARCA2 2441/4885SMARCA4 1901/4885KDR 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.